Imagine poking a balloon with a needle; usually, the air leaks out and the balloon collapses. This system acts like a tiny, instant plug that seals the hole as the needle goes in. It stops air from escaping the lung, preventing a dangerous collapse during cancer tests.
Lung biopsies carry a high risk of pneumothorax, which leads to expensive hospitalizations and delayed cancer diagnoses. Currently, there are no devices that successfully prevent this complication during the needle access phase.
A patented coaxial delivery needle and biodegradable hydrogel sealant system. The project delivered the design optimization and the validation data needed for regulatory approval.
If you are a device manufacturer dealing with high complication rates in lung biopsies — this project developed a biodegradable hydrogel sealant that prevents pneumothorax. This adds a 2-minute step to the standard care to stop air leaks.
If you are a clinic dealing with the high cost of biopsy complications — this project developed a pre-sealing system. It reduces the risk of patients requiring hospital admission, which can cost approximately €15k per case.
If you are a biotech firm dealing with the need for biodegradable surgical sealants — this project developed a coaxial delivery needle system. It demonstrates a practical application for hydrogels in preventing lung collapse during biopsy.
A lung biopsy with complications is approximately four times more expensive than one without. Preventing pneumothorax can avoid additional costs of care reaching approximately €15k.
Yes, the project description explicitly refers to the 'patented Selio Sealant System'.
The EU records approximately 320,000 new lung cancer cases per annum, all of which may require diagnosis via biopsy.
The project focuses on verification, validation testing, biocompatibility, and sterilization validation to prepare documentation for regulatory approval.
It is designed as a 2-minute 'add-on' to the current biopsy standard of care, used by an interventional radiologist before the biopsy takes place.
The project is led by a single SME, Selio Medical Limited, based in Ireland. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the project is lean and focused entirely on commercialization and regulatory approval rather than academic research.
Contact Selio Medical Limited in Ireland
Contact us to explore licensing opportunities for the Selio Sealant System.
